Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Castration-Resistant Prostate Cancer × PF06821497 × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 2 Prostatic Neoplasms 2 Small Cell Lung Carcinoma 1 Metastatic Castration-Resistant Prostate Cancer 1 Lymphoma, Follicular 1

Interventions

enzalutamide 2 inavolisib 1 abiraterone 1 PF06821497 1 Docetaxel 1 Diagnostic Tests, Routine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06629779 2026-03-19

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer

Phase 3 Recruiting

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡